North America had the highest 12-month cancer prevalence rate in 2022. The 12-month prevalence rate for all cancers in North America as of this time was 595 per 100,000 population. This statistic displays 12-month cancer prevalence rates worldwide in 2022, by region.

Introduction

Cancer Statistics: Cancer continues to be a major global health challenge, with significant increases in both incidence and mortality. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. The most common cancers included lung, breast, colorectal, prostate, and stomach cancers. The global cancer burden is projected to rise substantially, with estimates suggesting 35.3 million new cases and 18.5 million cancer-related deaths by 2050.

This increase is attributed to factors such as population growth, aging, and exposure to risk factors like tobacco use, obesity, and environmental pollutants. The economic impact of cancer is also profound, with direct medical costs in the United States alone reaching nearly $209 billion in 2020.

These statistics underscore the urgent need for enhanced prevention, early detection, and treatment strategies to address the growing cancer burden globally. The information is presented from a market researcher's point of view, incorporating the latest data and trends.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

According to Cognitive Market Research, the global Cancer Diagnosis market size will be USD 109614.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 32884.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The consumables category is the fastest growing segment of the Cancer Diagnosis industry

Market Dynamics of Cancer Diagnosis Market

Key Drivers for Cancer Diagnosis Market

Increasing Rate of Cancer Diagnostics to Boost Market Growth

The rising global incidence of cancer, which affects millions of people a year, is a primary driver of the need for diagnostic testing. Numerous factors contribute to this tendency, such as the aging population, which increases the risk of developing some cancers in older adults. Changes in lifestyle, including poor eating habits, inactivity, and increased use of alcohol and tobacco, have also contributed to an increase in cancer incidence. Environmental factors, such as exposure to chemicals and hazardous compounds, exacerbate the problem and increase the risk of developing cancer. Therefore, as early detection and diagnosis are becoming more and more important to patients and healthcare professionals, effective cancer diagnostics are essential. The market for cancer diagnostics is expanding as a result of the increased emphasis on prompt and precise cancer detection, which highlights the value of novel diagnostic procedures. For Instance, in 2023, the Pan American Health Organization (PAHO) projects that there will be 20 million new cases and 10 million deaths, and by 2040, nearly 30 million cases will be reported annually.

Innovations in Diagnostic Technologies to Drive Market Growth

The market for cancer diagnostics is expanding as a result of advancements in diagnostic technologies that have greatly improved the precision and effectiveness of cancer detection. For example, non-invasive cancer biomarker identification in physiological fluids is made possible by liquid biopsies, which offer vital insights into tumor dynamics and therapy response. In a similar vein, molecular diagnostics has transformed the detection of particular genetic abnormalities and changes linked to different types of cancer, allowing for more individualized treatment strategies. High-resolution images of tumors are provided by advanced imaging methods like MRI and PET scans, which help with accurate staging and localization. Better patient outcomes result from these technical developments because they increase overall diagnosis accuracy and enable early intervention. The ongoing development of these cutting-edge diagnostic instruments is propelling market expansion and revolutionizing cancer treatment.

Restraint Factor for the Cancer Diagnosis Market

The High Price of Cutting-Edge Diagnostic Technology Will Limit Market Growth

The market for cancer diagnostics is severely hampered by the high price of sophisticated diagnostic tools. Advanced diagnostic instruments, such as molecular tests and imaging technologies, are frequently expensive, which limits healthcare facilities' access to them, especially in settings with limited resources. These institutions' capacity to provide thorough cancer screening and diagnostic services is restricted by this financial barrier, which eventually affects patient outcomes. These financial difficulties are further exacerbated by the costs associated with the development, research, and regulatory approval of new diagnostic instruments. Companies have to spend a lot of money to comply ...

Introduction

Cancer Statistics: Cancer continues to pose a major global health challenge, ranking among the top causes of mortality and disease burden worldwide. New cancer cases are rising steadily, influenced by factors such as an aging population, changing lifestyles, and environmental factors. Reliable and current cancer data are essential for comprehending the disease's scale, shaping public health strategies, optimizing resource distribution, and driving scientific research.

These statistics provide a comprehensive overview of recent global cancer incidence, mortality, and survival trends, emphasizing prominent cancer types and geographical differences. Through this analysis, policymakers and healthcare professionals can better focus efforts on prevention, early diagnosis, and treatment to lessen Cancer's impact on communities globally.

In 2022, there were around 20 million new cases of cancer worldwide. It is predicted that this number will increase to around 35.3 million incident cases in the year 2050. This statistic shows the predicted number of new cancer cases worldwide from 2022 to 2050.

📄 Dataset Description: This dataset contains global cancer patient data reported from 2015 to 2024, designed to simulate the key factors influencing cancer diagnosis, treatment, and survival. It includes a variety of features that are commonly studied in the medical field, such as age, gender, cancer type, environmental factors, and lifestyle behaviors. The dataset is perfect for:

Exploratory Data Analysis (EDA)

Multiple Linear Regression and other modeling tasks

Feature Selection and Correlation Analysis

Predictive Modeling for cancer severity, treatment cost, and survival prediction

Data Visualization and creating insightful graphs

Key Features: Age: Patient's age (20-90 years)

Gender: Male, Female, or Other

Country/Region: Country or region of the patient

Cancer Type: Various types of cancer (e.g., Breast, Lung, Colon)

Cancer Stage: Stage 0 to Stage IV

Risk Factors: Includes genetic risk, air pollution, alcohol use, smoking, obesity, etc.

Treatment Cost: Estimated cost of cancer treatment (in USD)

Survival Years: Years survived since diagnosis

Severity Score: A composite score representing cancer severity

This dataset provides a broad view of global cancer trends, making it an ideal resource for those learning data science, machine learning, and statistical analysis in healthcare.

Users can access data about cancer statistics, specifically incidence and mortality worldwide for the 27 major types of cancer. Background Cancer Mondial is maintained by the Section of Cancer Information (CIN) of International Agency for Research on Cancer by the World Health Organization. Users can access CIN databases including GLOBOCAN, CI5(Cancer Incidence in Five Continents), WHO, ACCIS(Automated Childhood Cancer Information System), ECO (European Cancer Observatory), NORDCAN and Survcan. User functionality Users can access a variety of databases. CIN Databases: GLOBOCAN provides acces s to the most recent estimates (for 2008) of the incidence of 27 major cancers and mortality from 27 major cancers worldwide. CI5 (Cancer Incidence in Five Continents) provides access to detailed information on the incidence of cancer recorded by cancer registries (regional or national) worldwide. WHO presents long time series of selected cancer mortality recorded in selected countries of the world. Collaborative projects: ACCIS (Automated Childhood Cancer Information System) provides access to data on cancer incidence and survival of children collected by European cancer registries. ECO (European Cancer Observatory) provides access to the estimates (for 2008) of the incidence of, and mortality f rom 25 major cancers in the countries of the European Union (EU-27). NORDCAN presents up-to-date long time series of cancer incidence, mortality, prevalence and survival from 40 cancers recorded by the Nordic countries. SurvCan presents cancer survival data from cancer registries in low and middle income regions of the world. Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In a recent report it was shown that the U.S. has the highest prevalence of diagnosed cancer cases among all adults, with around * percent of the adult population having some cancer diagnosis. Cancer is the second leading cause of death from chronic diseases worldwide after cardiovascular diseases.

Global cancer risks

Globally, cancer accounts for about * in every 6 deaths. Many cancer cases are caused by behavioral and dietary risks including tobacco, alcohol and physical inactivity. The prevalence of tobacco smoking is on the decline and is expected to decline further in the future. Smoking has been linked to lung cancer, other upper respiratory cancers and chronic obstructive pulmonary disease (COPD). Among other cancer risk factors, alcohol consumption has been linked to liver and colorectal cancers, as well as other non-communicable diseases. Many European countries have high rates of alcohol consumption.

Global cancer prevalence

Globally, trachea, bronchus and lung cancers are responsible for the most cancer deaths, followed by liver cancer. Lifestyle modification is one of the easiest ways people can reduce their risk of these types of cancer. Among all cancer patients globally, a majority had a history of alcohol consumption. Similarly, in China, EU5 and Russia, over a quarter of all cancer patients had a history of smoking.

Annual percent change and average annual percent change in age-standardized cancer incidence rates since 1984 to the most recent diagnosis year. The table includes a selection of commonly diagnosed invasive cancers, as well as in situ bladder cancer. Cases are defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3) from 1992 to the most recent data year and on the International Classification of Diseases, ninth revision (ICD-9) from 1984 to 1991.

In 2022, there were an estimated 2.48 million new cases of trachea, bronchus, and lung cancer worldwide. Breast cancer was the second most common cancer type at that time with around 2.3 million new cases worldwide.

Number of new cancer cases

Cancer can be caused by internal factors like genetics and mutations, as well as external factors such as smoking and radiation. It occurs in the presence of uncontrolled growth and spread of abnormal cells. However, many cancer cases could be prevented, for example, by omitting cigarette usage and heavy alcohol consumption. Risk of developing cancer tends to increase with age and is most common in older adults. Nevertheless, cancer can develop in individuals of any age. Cancer can be treated through surgery, radiation, and chemotherapy, among other methods.

In the United States, there will be an estimated two million new cancer cases and 611,720 deaths in 2024. Among U.S. men, prostate cancer and lung and bronchus cancers are the most common cancer types as of 2024, totaling an estimated 299,010 and 116,310 cases, respectively. In women, breast cancer and lung and bronchus cancer are the most common newly diagnosed types, totaling 310,720 and 118,270 cases, respectively.

Blood cancer survival rates vary widely across the globe — and the contrast between India and developed nations is both eye-opening and urgent. While countries like the U.S., UK, and Germany report survival rates of 60–75% for common blood cancers such as leukaemia, lymphoma, and myeloma, India’s figures remain significantly lower, often ranging between 30 and 40%.This gap is driven by several critical factors: late diagnosis, limited access to advanced treatments, lack of awareness, and uneven healthcare infrastructure. Yet, with timely detection and modern therapies like CAR T-cell therapy and bone marrow transplant, these numbers can improve — and lives can be saved.At bmtnext.com, BMT NEXT is working to close this survival gap by offering world-class care, cutting-edge treatment options, and personalised support for every patient. Our mission is to ensure that patients in India receive the same level of care and hope as those in the most advanced healthcare systems.It’s time to bridge the divide — and BMT NEXT is leading the way.

Lung cancer is the deadliest cancer worldwide, accounting for 1.82 million deaths in 2022. The second most deadly form of cancer is colorectum cancer, followed by liver cancer. However, lung cancer is only the sixth leading cause of death worldwide, with heart disease and stroke accounting for the highest share of deaths. Male vs. female cases Given that lung cancer causes the highest number of cancer deaths worldwide, it may be unsurprising to learn that lung cancer is the most common form of new cancer cases among males. However, among females, breast cancer is by far the most common form of new cancer cases. In fact, breast cancer is the most prevalent cancer worldwide, followed by prostate cancer. Prostate cancer is a very close second to lung cancer among the cancers with the highest rates of new cases among men. Male vs. female deaths Lung cancer is by far the deadliest form of cancer among males but is the second deadliest form of cancer among females. Breast cancer, the most prevalent form of cancer among females worldwide, is also the deadliest form of cancer among females. Although prostate cancer is the second most prevalent cancer among men, it is the fifth deadliest cancer. Lung, liver, stomach, colorectum, and oesophagus cancers all have higher deaths rates among males.

cancer therapeutics and biotherapeutics Market Outlook

According to our latest research, the global cancer therapeutics and biotherapeutics market size stood at USD 195.8 billion in 2024, reflecting robust demand and innovation in oncology treatments. The market is projected to expand at a CAGR of 8.7% from 2025 to 2033, reaching an estimated USD 418.7 billion by 2033. This impressive growth is driven by the increasing incidence of cancer worldwide, rapid advancements in biotherapeutic modalities, and the ongoing introduction of novel, targeted therapies that enhance patient outcomes.

A key growth factor for the cancer therapeutics and biotherapeutics market is the rising global cancer burden. According to the World Health Organization, cancer remains one of the leading causes of morbidity and mortality worldwide, with over 20 million new cases and 10 million deaths in 2024. The aging population, lifestyle changes, environmental factors, and improved diagnostic capabilities are contributing to the escalating prevalence of various cancer types. This has led to a heightened demand for innovative and effective therapeutic solutions, spurring investments in research and development by both public and private entities. In particular, the emergence of precision medicine and personalized therapies has revolutionized cancer care, offering hope for improved survival rates and quality of life for patients.

Another significant driver is the rapid advancement and adoption of biotherapeutics, such as monoclonal antibodies, immune checkpoint inhibitors, and cell therapies. These modalities have demonstrated superior efficacy and safety profiles compared to traditional chemotherapies, leading to their widespread adoption in clinical practice. Pharmaceutical and biotechnology companies are increasingly focusing on the development of next-generation biotherapeutics, leveraging cutting-edge technologies like CRISPR, CAR-T, and bispecific antibodies. The expanding pipeline of innovative drugs, coupled with expedited regulatory approvals and favorable reimbursement policies in key markets, is accelerating the commercialization of novel cancer therapies and broadening patient access to life-saving treatments.

Furthermore, the integration of artificial intelligence, big data analytics, and digital health tools is transforming the landscape of cancer therapeutics and biotherapeutics. These technologies are enabling more accurate tumor profiling, better patient stratification, and optimized treatment regimens, ultimately leading to improved clinical outcomes. Collaborations between academic institutions, research organizations, and industry stakeholders are fostering a vibrant ecosystem for oncology innovation. Additionally, growing awareness among patients and healthcare providers about the benefits of targeted and immunotherapeutic approaches is driving uptake and supporting market expansion. The convergence of scientific breakthroughs, supportive policy frameworks, and patient-centric care models is expected to sustain the robust growth trajectory of the cancer therapeutics and biotherapeutics market over the forecast period.

Regionally, North America remains the dominant market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The United States, in particular, benefits from a well-established healthcare infrastructure, strong R&D capabilities, and high healthcare expenditure. However, the Asia Pacific region is witnessing the fastest growth, fueled by rising cancer incidence, increasing healthcare investments, and expanding access to advanced therapies in countries like China, Japan, and India. Europe continues to play a pivotal role, driven by supportive regulatory environments and active participation in global oncology research initiatives. Latin America and the Middle East & Africa are gradually emerging as promising markets, supported by improving healthcare access and growing awareness about cancer therapies.

Product Type Analysis

The cancer therapeutics and biother

Source: https://ourworldindata.org/cancer

The dataset titled "Cancer Types Causing Death," sourced from Our World in Data, provides a comprehensive overview of global cancer mortality trends. According to the dataset, lung cancer leads as the most fatal cancer worldwide, with approximately 1.8 million deaths in 2022, accounting for 18.7% of all cancer-related fatalities . Following lung cancer, colorectal cancer ranks second, causing about 900,000 deaths (9.3%), while liver cancer and breast cancer account for 760,000 (7.8%) and 670,000 (6.9%) deaths, respectively. Stomach cancer also remains a significant cause of death, with 660,000 fatalities (6.8%) .

The dataset highlights that lung cancer's prevalence is closely linked to tobacco use, particularly in regions like Asia. In contrast, breast cancer predominantly affects women, while colorectal cancer impacts both genders equally. Notably, the dataset indicates a decline in age-standardized death rates for certain cancers, such as stomach cancer, due to improved hygiene, sanitation, and antibiotic treatments targeting Helicobacter pylori infections . Our World in Data

Additionally, the dataset underscores the global disparity in cancer mortality, with approximately 70% of cancer deaths occurring in low- and middle-income countries . This disparity is attributed to factors like limited access to early detection, treatment, and preventive measures. The dataset serves as a valuable resource for understanding the global burden of cancer and the need for targeted public health interventions. World Health Organization

Number and rate of new cancer cases by stage at diagnosis from 2011 to the most recent diagnosis year available. Included are colorectal, lung, breast, cervical and prostate cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In 2022, there were over 9.7 million cancer deaths worldwide. It is projected that the number of deaths due to cancer worldwide will increase to almost 18.5 million by 2050. The most prevalent type of cancer in 2022 was breast cancer with around 48 prevalent cases per 100,000 population. However, lung cancer is by far the deadliest type of cancer.

Lung Cancer Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. In 2022, around 1.82 million cancer deaths, or 19 percent of all cancer deaths worldwide were attributed to lung cancer. Long-term smoking is known to be a major cause of lung cancer. People who never quit smoking are 24 percent more likely to die before age 65 than people who never smoked in their lives.

Treatment In 2023, it was estimated that there were around 4,492 cancer immunotherapy products in R&D phases, as well as another 3,622 other cancer products in the R&D product pipeline. In the same year, it was projected that there were 965 active drugs for breast cancer, as well as 925 active drugs for non-small cell lung cancer.

The Global Cancer Registry Software Market size was valued at USD 56.1 million in 2023 and is projected to reach USD 112.85 million by 2032, exhibiting a CAGR of 10.5 % during the forecasts period. Global Cancer Registry Software relates to the much-needed software systems for accumulating and processing cancer patients’ data in various centres. These software platforms allow clinics, hospitals and research institutions to monitor cases of cancer and other diseases to develop or to investigate epidemiological trends and clinical effectiveness. They are a central player in cancer screening, early detection prevention plans and evaluation of trends in the provision of health care services and community health. Examples of using the system are working with cancer cases, preparing reports to authorized bodies, follow up of the patients, and other interprofessional cooperation in research. It is incumbent to note that the current trends embrace the application of artificial intelligence in analyzing big data, use of cloud computing solutions, and a growing concern on the ability of the registries to interoperate as providers of health care information around the globe. The market development is based on the growing rates of cancer diseases globally, and the need to enhance the outcomes of cancer care by using advanced data management systems.

According to Cognitive Market Research, the global Cancer Cachexia market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of XX from 2024 to 2031.

• The global Cancer Cachexia market will expand significantly by XX% CAGR between 2024 and 2031. • North America held a market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Asia Pacific held the major market of more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Latin America's market will have more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • According to Cognitive Market Research, Progestogens is the dominant therapeutic segment for the cancer cachexia market. • According to Cognitive Market Research, Appetite Stimulators is the dominant mechanism action segment for the cancer cachexia market.

Key Dynamics of

Cancer Cachexia Market

Key Drivers of

Cancer Cachexia Market

Rising Global Cancer Incidence: The escalating number of cancer cases globally is directly linked to an increased occurrence of cachexia. As advancements in cancer treatment extend survival rates, the management of cachexia emerges as a vital aspect of palliative care.

Growing Awareness Among Healthcare Providers: Healthcare professionals are progressively acknowledging cachexia as a unique and manageable condition. This transformation is resulting in improved diagnosis, earlier interventions, and a heightened demand for specialized therapies.

Development of Novel Therapeutics: Pharmaceutical firms are channeling resources into groundbreaking treatments that tackle both weight loss and muscle atrophy. The development pipeline features anabolic agents, appetite enhancers, and anti-inflammatory medications, enhancing market opportunities.

Key Restraints for

Cancer Cachexia Market

Limited Approved Treatment Options: In spite of the considerable impact, there are only a handful of FDA-sanctioned medications specifically for cancer cachexia. This scarcity restricts physicians' capacity to deliver consistent and effective treatment across diverse patient groups.

Complex Pathophysiology and Diagnosis: Cancer cachexia encompasses a range of complex mechanisms, complicating its definition, diagnosis, and management. The absence of a unified agreement on clinical criteria frequently postpones appropriate treatment and restricts the adoption of therapeutic options.

Regulatory and Clinical Trial Challenges: Establishing clear endpoints in clinical trials poses difficulties due to the intricate nature of the disease. Regulatory ambiguities and sluggish trial advancements impede the prompt development and approval of new treatment options.

Key Trends in

Cancer Cachexia Market

Enhanced Emphasis on Multimodal Therapy: Healthcare practitioners are increasingly utilizing a blend of pharmacological, nutritional, and physical therapy methods. This comprehensive treatment strategy demonstrates potential in alleviating symptoms more efficiently than single-agent therapy.

Collaborations and Growth in Research Funding: The surge in both public and private investment for cachexia-related research is expediting the process of drug development. Collaborative efforts between biotechnology companies and academic institutions are additionally propelling innovation within this sector.

Patient-Focused Treatment Strategies: Customized care plans designed according to the type and stage of cancer, as well as the overall health of the patient, are becoming more prevalent. The focus is transitioning towards enhancing the quality of life, rather than solely concentrating on physical metrics such as body weight.

Impact of COVID-19 on the Can...